Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation (Study P05876)
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The investigation will be conducted to define safety and efficacy under the conditions of
post-marketing use of this drug in subjects with allergic rhinitis.
Post-marketing surveys are not considered applicable clinical trials and thus the results of
this survey will not be posted at its conclusion. The results will be submitted to public
health officials as required by applicable national and international laws.